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This study was designed in order to evaluate the association between the single 
nucleotide polymorphism (SNP) 309 in the MDM2 gene with head and neck squamous 
cell carcinoma (HNSCC). An MDM2 protein downregulates the p53 pathway. Recently, 
an important SNP was discovered in the MDM2 promoter region, which could affect the 
tumorigenesis of HNSCC by attenuation of the p53 pathway. 
Material and Methods 
Patients with 103 HNSCC were genotyped using direct sequencing and real-time PCR. 
The relationship between the SNP309 genotypes and the clinicopathological features 
was statistically analyzed. 
Results 
The number of patients genotyped to TT, TG, and GG was 29, (28%), 46 (44.7%), and 
28 (27.2%), respectively. The average age of tumor onset was 65.6 years in the TT, 62.9 
years in the TG, and 56.7 years in the GG. The patients with the GG genotype had a 
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significantly earlier tumor onset in comparison to those with the TT genotype (P = 
0.032).  
Conclusions 
The GG genotype of MDM2-SNP309 is associated with an earlier onset of HNSCC in 
the Japanese population. SNP309 may be a key factor in the tumorigenesis of HNSCC 














  Malignant neoplasms are known to occur due to multi-step genetic alterations 
in tumorigenesis (1). The murine double minute 2 (MDM2) gene was originally 
identified to be an amplified gene on a murine double minute chromosome in the 
transformed BALB/c 3T3 cell line. A MDM2 protein forms a complex with the p53 
protein and promotes the rapid degradation of the p53 protein. As the p53 gene product 
plays a central role in cell cycle regulation, such as cell cycle arrest, cellular senescence, 
and apoptosis (2-3). These p53-regulated pathways are frequently inactivated in human 
tumors both by gene alterations, or cellular/viral proteins binding to p53 protein. 
Genetic alterations of p53 have been reported in various types of epithelial tumors, 
including head and neck squamous cell carcinoma (HNSCC). Such mutations of p53 
gene were observed approximately 40-50% of the HNSCC (4). 
        The interaction between the p53 and MDM2 proteins inhibits both cell cycle 
arrest and apoptotic functions (5-7). In vitro, the overexpression of MDM2 in the 
murine cells has been shown to increase the tumorigenic potential and growth rate (7-8). 
In addition, the overexpression of the MDM2 gene product and/or gene amplification 
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has been frequently found in human malignant tumors, especially in sarcomas and soft 
tissue tumors (9). Therefore, these data suggest the oncogenic role of MDM2 in several 
tumor models.  
  Recently, a single nucleotide polymorphism (SNP), i.e., a T to G substitution 
at the first intron, was discovered in the MDM2 promoter region, which was named 
SNP309 (10). Interestingly, in Li-Fraumeni Syndrome patients, who have a somatic 
mutation in the TP53 gene, those with SNP309 showed a significantly earlier age of 
onset for malignant tumors in the form of sarcomas and breast cancer. Moreover, the G 
allele of SNP309 was associated with an earlier tumor onset of sporadic soft tissue 
sarcoma. These data suggest that the G allele of SNP309 is associated with the 
acceleration of tumorigenesis by attenuation of the p53 tumor suppressor pathway. The 
study conducted in Finland reported no association between SNP309 and HNSCC (11). 
However, the relationship between SNP309 and HNSCC has not yet been elucidated in 
other ethnic populations.  
        Estrogen signaling has been shown to regulate MDM2 expression levels. 
Previous study suggested that G allele of SNP309 increases the affinity of the promoter 
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for Sp1, which is a transcriptional activator for multiple hormone receptors, including 
estrogen receptor (ER) (12). Since the effects of overexpressed MDM2 may be 
enhanced by ER interactions with Sp1, SNP309 could affect gender differences on 
tumorigenesis and susceptibility in different types of cancer (10-13). In order to 
investigate the above issues in Japanese patients with HNSCC, we investigated the 













Materials and Methods 
 
Patients and Controls 
  This study included 103 patients with HNSCC and 120 cancer-free controls. 
Table 1 shows detailed information about the characteristics of the HNSCC patients (84 
males, 19 females). The average age of patients at diagnosis was 62.0 years (range 
18-92 years, SD±13.4). The most common tumor site was the larynx (n=40), followed 
by the hypopharynx (n=14), oral cavity (n=13), nasopharynx (n=12), and oropharynx 
(n=12). Seventy-six patients (73.8%) were smoker (male: 70/84, female: 6/19) and 55 
patients (54.1%) were habitual alcohol drinker (male: 55/84, female: 0/19). The female 
patients’ group was consisted of mostly postmenopausal women (89.5%, 17 of the 19 
patients), and no one had taken exogenous estrogens. Table 2 shows information about 
cancer-free controls. The cancer-free control cohort consisted of 59 males and 61 
females. The average age of the patients was 33.7 years (range 16-78 years, SD±13.5). 
All of the subjects were genetically unrelated Japanese; they were from Kanazawa, 
Japan and the surrounding regions. All of the patients had histopathologically confirmed 
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HNSCC and were diagnosed and recruited from December 2003 to March 2005 at the 
Department of Otolaryngology of Kanazawa University Hospital. Written informed 
consent was obtained from each subject at recruitment. This study was approved by the 
institutional review board of Kanazawa University. 
 
Genetic Analysis 
  A 3 mL blood sample was collected from the patients and the controls. The 
genomic DNA was extracted using a QIAamp® DNA Mini Kit (QIAGEN, Hilden, 
Germany). The MDM2 SNP309 was genotyped by genomic sequencing and real-time 
PCR (RT-PCR). In order to confirm the result of RT-PCR, we performed direct genomic 
sequencing. Genotyping was performed without knowledge of patient or control status 
of the study subjects. The sequencing PCR primers that were used in the reactions 
were as follows: 5’-GTTCAGGGTAAAGGTCACG-3’ and 
5’-GTCTGAACTTGACCAGCTC-3’. PCR was performed in 100 μl volumes 
containing 100 ng genomic DNA, 10×PCR buffer, 2.5 mmol each dNTP mixture, 0.1 
μmol of both primers, and 2.5 U of Takara Ex Taq DNA polymerase (TAKARA BIO, 
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Otsu, Japan).  
  PCR was carried out with an initial melting step of 5 min at 94oC, followed by 
40 cycles of 30 sec at 94oC, 30 sec at 62oC, and 30 sec at 72oC, and a final elongation 
step of 7 min at 72oC. The PCR products were purified using a QIAGEN quick PCR 
Purification Kit (QIAGEN), and then sequenced using an ABI PRISM 310 sequencing 
system (Applied Biosystems, Foster City, CA). 
  RT-PCR was performed utilizing a Light-Cycler (Roche, Mannheim, 
Germany) with hybridization probes in combination with the Light-Cycler DNA master 
hybridization probes kit (Roche). The PCR primers were the same as those used in 
sequencing. SNP analysis on the Light-Cycler instrument using melting curve analysis 
represents amplification and detection with specific probes. The hybridization probes 
were as follows: 5’-LC Red-CGCGCCGCAGCGGCC-3’ and 
5’-CAGGCACCTGCGATCATCCGGACCTC-Fluorescein. The hybridization probes 
were synthesized by Nihon Gene Research Laboratories (Sendai, Japan). The PCR 
reaction mixture consisted of 2 mM MgCl2, 4 pmol of each hybridization probe, 10 
pmol of each PCR primer, 2 μl of Light-Cycler DNA master hybridization mix (Roche), 
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and 10 ng of DNA in a final volume of 20 μl. After 10 min of denaturation at 95oC, the 
PCR cycles were performed with 10 sec denaturation at 95oC, 10 sec annealing at 59oC, 
and 8 sec extension at 72oC for 45 cycles. The melting curves were achieved following 
a start temperature of 40oC and an end temperature of 95oC with a temperature increase 
of 0.05oC /sec. MDM2 SNP309 genotypes were differentiated based on melting 




  The genotype frequency was analyzed using the χ2 test. The correlation 
between MDM2-SNP309 and age at tumor onset was studied with one-way ANOVA, 
and post hoc analyses of the differences among the means were performed using the 
Tukey-Kramer multiple comparison test. The tumor onset age separated patients into 
male and female were compared with Fisher’s protected least significant difference 
(PLSD) test. P values of < 0.05 were considered to be significant. All of the statistical 
analysis was performed with the Dr. SPSSⅡsoftware program for Windows (SPSS, 
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Analysis of MDM2-SNP309  
  The genotype and distribution of the MDM2 SNP309 in the controls and 
patients are shown in Table 3. In the controls, 37 individuals (30.8%) were wild type 
(TT), 50 (41.7%) were heterozygous (TG), and 33 (27.5%) were homozygous (GG) for 
SNP309. In the HNSCC patients, 29 individuals (28.2%) were TT, 46 (44.7%) were TG, 
and 28 (27.2%) were GG for SNP309. In the male patients, 24 individuals were TT 
genotype, 38 were TG, and 22 were GG for SNP309. In the female, 6 individuals were 
TT, 8 were TG, and 5 were GG for SNP309. The observed genotype frequency of the 
patients was in agreement with the Hardy-Weinberg equilibrium in the controls. There 
was no significant difference between the patient groups and the controls regarding the 
distribution of genotypes. 
 
Tumor Onset of HNSCC 
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  The average age of tumor onset in the HNSCC patients was 65.6 years in the 
TT group, 62.9 years in the TG group, and 56.7 years in the GG group, respectively. 
Figure 1 shows the distributions of the age at diagnosis for each genotype. The median 
age at diagnosis was 70 years in the TT genotype, 64 years in the TG, and 58 years in 
the GG (Table 4). A significant difference was observed in the average age of tumor 
onset between the TT and GG groups (P = 0.032), but no significant differences were 
observed between the TT and TG groups (P = 0.67), or between the TG and GG groups 
(P = 0.12), respectively. These results indicate that patients with the GG genotype 
develop HNSCC earlier than those with the TT genotype. 
  Since several reports suggest this SNP restricted with female, we also 
investigated whether this SNP associated with gender. Figure 2 shows the tumor onset 
age separated the patients into female and male for each genotype. The average 
diagnosed age of the male HNSCC patients was 65.2 years in the TT group, 63.2 years 
in the TG, and 57.0 years in the GG. These data are similar to the result from all of the 
HNSCC patients, and significant difference was observed in the average age between 
the TT and GG groups of male (P = 0.47). In the female patients, the average diagnosed 
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age was 67.4 years in the TT group, 61.6 years in the TG group, and 55.5 years in the 
GG group. These results are similar to those of all HNSCC patients. In spite of 11.9 
years earlier tumor onset was observed, there was no statistically significant association 
between the different genotypes and tumor onset age in the female patients (P = 0.086). 
 
Association of MDM2-SNP309 with Clinical Status of HNSCC 
  We evaluated the effects of MDM2 SNP309 on the clinical status of HNSCC 
at the time of diagnosis. However, there was no statistically significant association 
between SNP309 and primary tumor stage (T classification), lymph node stage (N 
classification), and the overall stage (data not shown). The average Brinkman Index (BI) 
of patients was 919.1 (SE±142.7) in the TT group, 733.5 (SE±91.5) in the TG group, 
and 653.7 (SE±130.2) in the GG group. The BI showed a decreasing tendency 
according to an increase the number of G alleles. However, there was no statistically 
significant association between MDM2 SNP309 and the smoking status. Similarly, there 
was no association between MDM2 SNP309 and alcohol consumption (data not shown). 
In addition, no significant association was observed between SNP309 and status of the 
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  MDM2 is known to be an oncogene, and its product is one of the essential 
negative regulators of p53 (14). Various human tumors show an overexpression of the 
MDM2 protein with or without the MDM2 gene amplification. Moreover, an 
overexpression of the MDM2 protein has been reported to correlate with a poor 
prognosis. In such tumors, an overexpression of MDM2 probably plays an important 
role in tumorigenesis, thus causing the suppression of tumor suppressor p53, or other 
mechanisms. 
  A previous study demonstrated that MDM2 SNP309 with a G allele has a 
strong potential toward tumorigenesis (10). The presence of the G allele could increase 
the affinity of the stimulatory protein 1 (Sp1) to this region of the MDM2 promoter, 
resulting in higher levels of MDM2 RNA and protein and the subsequent attenuation of 
the p53 pathway. Therefore, the naturally occurring variations in the MDM2 gene may 
influence an individual’s susceptibility to cancer by affecting the p53 signal 
transduction. On the other hand, the clinical role of SNP309 remains controversial 
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(10-13, 15-36). Regarding sporadic cancers, many previous studies showed that 
SNP309 was associated with an earlier onset of cancer, or an increased risk of cancer 
(11-13, 15-32). In contrast, several investigators reported no association between 
SNP309 and cancer (33-36). Few reports have examined the relationship between 
SNP309 and the risk of developing squamous cell carcinoma, but Hong et al reported an 
association between the MDM2 SNP309 GG genotype and a risk of developing poorly 
differentiated and advanced esophageal squamous cell carcinoma in comparison to the 
GT or TT genotypes (21).  In addition, Zhou et al. reported SNP309 associated with 
increased risk of nasopharyngeal carcinoma (NPC) occurrence and advanced neck 
lymph node metastasis of NPC (32). Similarly, our results demonstrated that the GG 
genotype, not existence of the G allele, in SNP309 is significantly associated with an 
earlier tumor onset in HNSCC patients in comparison to the TT genotype cohort. In 
contrast, a report showed no significant association between the SNP309 genotype and 
tumor onset in HNSCC patients in the Finnish population, suggesting that a difference 
in ethnicity affects the tumorigenic potential of the GG genotype in SNP309 (11). 
Previous studies demonstrated that the G-allele of SNP309 accelerates tumorigenesis of 
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diffuse large B-cell lymphoma, soft tissue sarcoma, breast cancer, and colorectal cancer 
in women (10-13). Our results showed an 11.9-years earlier tumor onset in women with 
the GG genotype and an 8.2-years earlier onset in men with the GG genotype compared 
with TT. There was significant difference was observed in men (P = 0.047), . However, 
there was no statically significance in women (P = 0.086), in spite of 11.9 years earlier 
tumor onset was observed. This is probably because the number of women is too small 
(n=19). This is come from the majority of HNSCC patients is men, because HNSCC is 
strongly related with habits of cigarette smoking and alcohol drinking, and the 
prevalence of women is low in HNSCC. Previous study demonstrated that increasing 
estrogen levels and ER signaling in women with the GG genotype could increase their 
risk to develop cancers. However, in our study, most of women were postmenopausal 
state and we could not observe gender-specific difference with tumor development. 
Therefore, we consider the estrogen levels and ER signaling is not strongly affect in 
HNSCC development. Moreover, both male and female showed the trend toward earlier 
tumor onset with the GG genotype compared with TT in our study. Thus, SNP309 may 
contribute to acceleration of tumor formation independent from influence of estrogen 
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hormone or ER signaling upon HNSCC. In addition, thus suggesting that the 
gender-associated effect of SNP309 on tumorigenesis varies according to the anatomic 
site in which the cancer develops. More studies will be necessary involving cancers of 
various anatomic sites with a larger sample size, especially women involved in, in order 
to elucidate this issue. 
  In addition, the HPV infection status is known to correlate with some of 
HNSCC, especially tonsillar carcinoma (37-38). A larger study may reveal the 
relationship between HPV infection and mdm2. 
        This study suggests that the SNP genotype provides interesting information, 
including predisposition to HNSCC, which is represented by early onset age. However, 
a larger scale prospective study examining the relationship between SNP 309 and p53 
status is called for. 
  In conclusion, the GG genotype of MDM2 SNP309 is associated with an 
earlier onset of HNSCC in the Japanese population according to our results. These 
results suggest that MDM2 SNP309 may affect the tumorigenic potential of the head 
and neck mucosa in the Japanese population, which eventually results in the earlier 
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Figure 1 shows the distributions of the age of HNSCC patients at diagnosis for each 
genotype. 
 
Figure 2 shows mean tumor onset age separated the patients into male and female for 
each genotype. Vertical bars indicate 95% CI. 
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Table 1. Characteristics of HNSCC Patients 
Characteristics Number of Patients (%)
Total patients 103 (100)
Sex  
  Male 84 (81.6)
  Female 19 (18.4)
Age  
  60≦ 48 (46.6)
  60 > 55 (53.4)
Tumor site  
  Larynx 40 (38.8)
  Hypopharynx 14 (13.6)
  Oral cavity 13 (12.6)
  Nasopharynx 12 (11.7)
  Oropharynx 12 (11.7)
  Paranasal sinuses 8 (7.8)
  Ear canal 3 (2.9)
  Primary unknown 1 (1.0)
T classification  
  1+2 59 (57.3)
  3+4 43 (41.7)
N classification  
  N0 57 (55.3)
  N1-3 46 (44.7)
Overall stage  
  Ⅰ+Ⅱ 45 (43.7)






Table 2. Characteristics of Controls 
Characteristics Number of Controls (%)
Total Controls 120 (100)
Sex  
  Male 59 (49.2)
  Female 61 (50.8)
 
 
Table 3. The Number of MDM2 SNP309 Genotype of the Controls, Patients, and  
Male or Female Patients 
   SNP309 No. Controls (%) No. Patients (%) Male Patients (%) Female Patients (%)
   TT 37 (30.8) 29 (28.2) 24 (28.6) 5 (26.3) 
   TG 50 (41.7) 46 (44.7) 38 (45.2) 8 (42.1)  
   GG 33 (27.5) 28 (27.2) 22 (26.2) 6 (31.6) 
   Total No. 120 103 84 19  
 
 
Table 4. MDM2 SNP309 status with the Average and Median Tumor Onset Age of Patients
SNP309 Tumor Onset Age (mean±SD) Median age 
TT 65.6±14.3* 70 
TG             62.9±11.4 64 
 
GG 56.7±14.3* 58 
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